好中球減少症生物学的製剤治療の世界市場レポート 2025年

好中球減少症生物学的製剤治療市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は6.5%で、181億米ドルに成長します。予測期間の成長は、ヘルスケアコスト管理、患者中心のケアモデル、併用療法の開発、規制の変更と承認、個別化医療アプローチなどに起因すると考えられます。予測期間の世界の動向には、世界市場へのアクセス、製造技術の進歩、治療プロトコルの合理化、バイオシミラーの採用、長時間作用型製剤の開発などが含まれます。

世界のがん患者の増加は、好中球減少症生物学的製剤治療市場の拡大に寄与すると予想されます。がんの罹患率の増加は、化学療法を受ける患者の増加と相まって、好中球減少症の有病率の増加につながっています。例えば、2022年1月の時点で、米国がん協会は、米国で約190万人が新たにがんと診断され、60万9,360人ががんに関連して死亡し、1日平均約1,670人が死亡すると予測しています。肺がん、前立腺がん、腸がん、女性の乳がんを合わせると、世界中で新たに発生するがんの43％を占める。したがって、世界のがん罹患率の急増は、今後数年間における好中球減少症生物学的製剤治療の需要を促進すると予想されます。

ヘルスケアの研究開発を目的とした政府のイニシアチブは、好中球減少症生物学的製剤治療市場の成長を促進する態勢を整えています。これらのイニシアチブは、特定の問題に対処し、定義された目標を達成し、社会に前向きな変化をもたらすために、さまざまなレベル（地方、地域、国、または国際）の政府当局によって行われる特定の行動、プログラム、政策、またはプロジェクトを包含しています。様々な政府機関が、好中球減少症生物学的製剤治療を含む様々な側面を支援するために、ヘルスケアのイニシアチブを開始しています。その一例として、2022年、英国政府はヘルスケア社会介護省を通じて、ヘルスケアの研究と製造を促進するために2億6,000万ポンド（2億7,065万米国ドル）の資金拠出を発表しました。BEISとDHSCによるこの配分は、新しいプライバシー保護プラットフォームと臨床研究サービスを通じて、診断と治療におけるNHS主導の医療研究を支援することを意図しています。さらに、英国におけるライフサイエンス製造業の拡大を促進するために、6,000万ポンド（6,360万米国ドル）が計上されました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の好中球減少症生物学的製剤治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の好中球減少症生物学的製剤治療市場：成長率分析
• 世界の好中球減少症生物学的製剤治療市場の実績：規模と成長、2019年～2024年
• 世界の好中球減少症生物学的製剤治療市場の予測：規模と成長、2024年～2029年、2034年
• 世界の好中球減少症生物学的製剤治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の好中球減少症生物学的製剤治療市場：薬剤タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• フィルグラスチム
• ペグフィルグラスチム
• レノグラスチム
• リペグフィルグラスチム
• サルグラモスチム
• 世界の好中球減少症生物学的製剤治療市場：治療タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 抗生物質
• 顆粒球コロニー刺激因子（G-CSF）
• 抗真菌薬
• その他の治療の種類
• 世界の好中球減少症生物学的製剤治療市場：流通チャネル別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 小売薬局
• 病院薬局
• オンライン薬局
• 世界の好中球減少症生物学的製剤治療市場、フィルグラスチムの種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• ブランド名の例：ニューポジェン
• 適応症および使用法
• 世界の好中球減少症生物学的製剤治療市場、ペグフィルグラスチムの種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• ブランド名の例：Neulasta
• 適応症および使用法
• 世界の好中球減少症生物学的製剤治療市場、レノグラスチムの種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• ブランド名の例：Granocyte
• 適応症および使用法
• 世界の好中球減少症生物学的製剤治療市場、リペグフィルグラスチムの種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• ブランド名の例：Lonquex
• 適応症および使用法
• 世界の好中球減少症生物学的製剤治療市場、サルグラモスチムの種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• ブランド名の例：Leukine
• 適応症および使用法

第7章 地域別・国別分析

• 世界の好中球減少症生物学的製剤治療市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 世界の好中球減少症生物学的製剤治療市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 好中球減少症生物学的製剤治療市場：競合情勢
• 好中球減少症生物学的製剤治療市場：企業プロファイル
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline plc
• F. Hoffmann-La Roche Ltd
• Merck & Co. Inc.
• Johnson & Johnson
• Baxter International Inc.
• Mylan N.V.
• Celgene Corporation
• Biogen Inc.
• AbbVie Inc.
• Regeneron Pharmaceuticals Inc.
• AstraZeneca plc
• Eli Lilly and Company
• Takeda Pharmaceutical Company Limited
• Bayer AG
• Sun Pharmaceutical Industries Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 好中球減少症生物学的製剤治療市場2029年：新たな機会を提供する国
• 好中球減少症生物学的製剤治療市場2029年：新たな機会を提供するセグメント
• 好中球減少症生物学的製剤治療市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Neutropenia biologic drug treatment involves the use of medications aimed at reducing fevers, preventing potential infections, and stimulating bone marrow activity to enhance neutrophil production. Neutropenia, characterized by a deficiency of neutrophils, a specific type of white blood cell, necessitates such interventions.

The primary drugs utilized in neutropenia biologic drug treatment include filgrastim, pegfilgrastim, lenograstim, lipegfilgrastim, and sargramostim. Filgrastim, a synthetic version of granulocyte colony-stimulating protein, is administered through injections to elevate neutrophil production following chemotherapy. Various types of treatments encompass antibiotic drugs, granulocyte-colony-stimulating factor (G-CSF), antifungal drugs, among others. These medications are accessible through diverse channels, including retail pharmacies, hospital pharmacies, and online pharmacies.

The neutropenia biologic drug treatment market research report is one of a series of new reports from The Business Research Company that provides neutropenia biologic drug treatment market statistics, including global market size, regional shares, competitors with a neutropenia biologic drug treatment market share, detailed neutropenia biologic drug treatment market segments, market trends and opportunities, and any further data you may need to thrive in the neutropenia biologic drug treatment industry. This neutropenia biologic drug treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neutropenia biologic drug treatment market size has grown strongly in recent years. It will grow from $13.22 billion in 2024 to $14.08 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to market access and reimbursement, patient advocacy and awareness, physician education and training, biologic drug development, clinical trial success.

The neutropenia biologic drug treatment market size is expected to see strong growth in the next few years. It will grow to $18.1 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to healthcare cost management, patient-centric care models, combination therapies development, regulatory changes and approvals, personalized medicine approaches. Major trends in the forecast period include global market accessibility, advancements in manufacturing techniques, treatment protocol streamlining, biosimilar adoption, development of long-acting formulations.

The increase in global cancer cases is expected to contribute to the expansion of the neutropenia biologic drugs market. The growing incidence of cancer, coupled with a rise in individuals undergoing chemotherapy, has led to an increased prevalence of neutropenia. For example, as of January 2022, the American Cancer Society projected approximately 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, averaging around 1,670 fatalities per day. Lung, prostate, bowel, and female breast cancer collectively represent 43 percent of all new cancer cases worldwide. Consequently, the surge in global cancer incidence rates is anticipated to drive demand for neutropenia biologic drug treatment in the coming years.

Government initiatives aimed at research and development in healthcare are poised to propel the Neutropenia biologic drug treatment market's growth. These initiatives encompass specific actions, programs, policies, or projects undertaken by government authorities at different levels (local, regional, national, or international) to address specific issues, achieve defined goals, or bring about positive changes in society. Various government bodies are launching healthcare initiatives to support different facets, including neutropenia biologic drug treatment. As an illustration, in 2022, the UK government, through the Department of Health and Social Care, announced a funding commitment of £260 million (US $270.65 million) to boost healthcare research and manufacturing. This allocation by BEIS and DHSC is intended to support NHS-led health research in diagnostics and treatment through new privacy-preserving platforms and clinical research services. Additionally, £60 million (US $63.60 million) was earmarked to facilitate the expansion of life sciences manufacturing in the UK.

Leading companies in the neutropenia biologic drug treatment sector are focusing on developing biosimilars to provide more affordable alternatives to existing biologics. Biosimilars are biologic medications designed to be nearly identical to an already approved reference biologic, exhibiting no significant differences in safety or effectiveness. For example, in May 2023, Amneal Pharmaceuticals, a US-based pharmaceutical company, launched Fylnetra (pegfilgrastim-pbbk), a biosimilar to Neulasta, which is intended to treat and prevent febrile neutropenia in patients undergoing chemotherapy. This biosimilar binds to specific receptors on hematopoietic cells, stimulating the proliferation and differentiation of neutrophil precursors in the bone marrow. Consequently, it enhances the production of neutrophils, which are vital for combating infections, especially in patients receiving myelosuppressive chemotherapy, thus reducing the occurrence of febrile neutropenia related to cancer treatments.

Major players in the neutropenia biologic drug treatment market are focusing on the development of innovative biosimilars, such as pegfilgrastim-pbbk (Fylnetra), to drive market revenues. For instance, in May 2023, Amneal Pharmaceuticals Inc. launched Fylnetra, a biosimilar referencing Neulasta and approved by the Food and Drug Administration (FDA) for the treatment of neutropenia. Fylnetra is available in a convenient pre-filled single-dose syringe.

In November 2022, Biocon Biologics, specializing in the development of biological drugs, acquired Viatris, a US-based company known for developing neutropenia biologic drugs such as pegfilgrastim. This acquisition further strengthens Biocon Biologics' capabilities in research and development, global-scale manufacturing, and commercialization in emerging markets within the biosimilars sector.

Major companies operating in the neutropenia biologic drug treatment market include Amgen Inc., Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Johnson & Johnson, Baxter International Inc., Mylan N.V., Celgene Corporation, Biogen Inc., AbbVie Inc., Regeneron Pharmaceuticals Inc., AstraZeneca plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Bayer AG, Sun Pharmaceutical Industries Ltd., Lupin Limited, Fresenius SE & Co. KGaA, Gilead Sciences Inc., Daiichi Sankyo Company, Kyowa Kirin Co. Ltd., CSL Limited, Dr. Reddy's Laboratories Ltd., Bristol-Myers Squibb Company, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd.

North America was the largest region in the neutropenia biologic drug treatment market in 2024. The regions covered in the neutropenia biologic drug treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the neutropenia biologic drug treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The neutropenia biologic drug treatment market consists of sales of cefepime, ceftazidime, piperacillin-tazobactam, and meropenem. Values in this market are 'factory gate values', that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neutropenia Biologic Drug Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neutropenia biologic drug treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neutropenia biologic drug treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neutropenia biologic drug treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Filgrastim; Pegfilgrastim; Lenograstim; Lipegfilgrastim; Sargramostim
• 2) By Treatment Type: Antibiotic Drugs; Granulocyte-Colony-Stimulating Factor (G-CSF); Antifungal Drugs; Other Treatment Types
• 3) By Distribution Channel: Retail Pharmacies; Hospital Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Filgrastim: Brand Name Examples: Neupogen; Indications And Usage
• 2) By Pegfilgrastim: Brand Name Examples: Neulasta; Indications And Usage
• 3) By Lenograstim: Brand Name Examples: Granocyte; Indications And Usage
• 4) By Lipegfilgrastim: Brand Name Examples: Lonquex; Indications And Usage
• 5) By Sargramostim: Brand Name Examples: Leukine; Indications And Usage
• Companies Mentioned: Amgen Inc.; Pfizer Inc.; Novartis AG; Teva Pharmaceutical Industries Ltd.; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Neutropenia Biologic Drug Treatment Market Characteristics

3. Neutropenia Biologic Drug Treatment Market Trends And Strategies

4. Neutropenia Biologic Drug Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Neutropenia Biologic Drug Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Neutropenia Biologic Drug Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Neutropenia Biologic Drug Treatment Market Growth Rate Analysis
• 5.4. Global Neutropenia Biologic Drug Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Neutropenia Biologic Drug Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Neutropenia Biologic Drug Treatment Total Addressable Market (TAM)

6. Neutropenia Biologic Drug Treatment Market Segmentation

• 6.1. Global Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Filgrastim
• Pegfilgrastim
• Lenograstim
• Lipegfilgrastim
• Sargramostim
• 6.2. Global Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antibiotic Drugs
• Granulocyte-Colony-Stimulating Factor (G-CSF)
• Antifungal Drugs
• Other Treatment Types
• 6.3. Global Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• 6.4. Global Neutropenia Biologic Drug Treatment Market, Sub-Segmentation Of Filgrastim, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Brand Name Examples: Neupogen
• Indications And Usage
• 6.5. Global Neutropenia Biologic Drug Treatment Market, Sub-Segmentation Of Pegfilgrastim, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Brand Name Examples: Neulasta
• Indications And Usage
• 6.6. Global Neutropenia Biologic Drug Treatment Market, Sub-Segmentation Of Lenograstim, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Brand Name Examples: Granocyte
• Indications And Usage
• 6.7. Global Neutropenia Biologic Drug Treatment Market, Sub-Segmentation Of Lipegfilgrastim, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Brand Name Examples: Lonquex
• Indications And Usage
• 6.8. Global Neutropenia Biologic Drug Treatment Market, Sub-Segmentation Of Sargramostim, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Brand Name Examples: Leukine
• Indications And Usage

7. Neutropenia Biologic Drug Treatment Market Regional And Country Analysis

• 7.1. Global Neutropenia Biologic Drug Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Neutropenia Biologic Drug Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neutropenia Biologic Drug Treatment Market

• 8.1. Asia-Pacific Neutropenia Biologic Drug Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neutropenia Biologic Drug Treatment Market

• 9.1. China Neutropenia Biologic Drug Treatment Market Overview
• 9.2. China Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neutropenia Biologic Drug Treatment Market

• 10.1. India Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neutropenia Biologic Drug Treatment Market

• 11.1. Japan Neutropenia Biologic Drug Treatment Market Overview
• 11.2. Japan Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neutropenia Biologic Drug Treatment Market

• 12.1. Australia Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neutropenia Biologic Drug Treatment Market

• 13.1. Indonesia Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neutropenia Biologic Drug Treatment Market

• 14.1. South Korea Neutropenia Biologic Drug Treatment Market Overview
• 14.2. South Korea Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neutropenia Biologic Drug Treatment Market

• 15.1. Western Europe Neutropenia Biologic Drug Treatment Market Overview
• 15.2. Western Europe Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neutropenia Biologic Drug Treatment Market

• 16.1. UK Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neutropenia Biologic Drug Treatment Market

• 17.1. Germany Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neutropenia Biologic Drug Treatment Market

• 18.1. France Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neutropenia Biologic Drug Treatment Market

• 19.1. Italy Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neutropenia Biologic Drug Treatment Market

• 20.1. Spain Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neutropenia Biologic Drug Treatment Market

• 21.1. Eastern Europe Neutropenia Biologic Drug Treatment Market Overview
• 21.2. Eastern Europe Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neutropenia Biologic Drug Treatment Market

• 22.1. Russia Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neutropenia Biologic Drug Treatment Market

• 23.1. North America Neutropenia Biologic Drug Treatment Market Overview
• 23.2. North America Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neutropenia Biologic Drug Treatment Market

• 24.1. USA Neutropenia Biologic Drug Treatment Market Overview
• 24.2. USA Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neutropenia Biologic Drug Treatment Market

• 25.1. Canada Neutropenia Biologic Drug Treatment Market Overview
• 25.2. Canada Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neutropenia Biologic Drug Treatment Market

• 26.1. South America Neutropenia Biologic Drug Treatment Market Overview
• 26.2. South America Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neutropenia Biologic Drug Treatment Market

• 27.1. Brazil Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neutropenia Biologic Drug Treatment Market

• 28.1. Middle East Neutropenia Biologic Drug Treatment Market Overview
• 28.2. Middle East Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neutropenia Biologic Drug Treatment Market

• 29.1. Africa Neutropenia Biologic Drug Treatment Market Overview
• 29.2. Africa Neutropenia Biologic Drug Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Neutropenia Biologic Drug Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Neutropenia Biologic Drug Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neutropenia Biologic Drug Treatment Market Competitive Landscape And Company Profiles

• 30.1. Neutropenia Biologic Drug Treatment Market Competitive Landscape
• 30.2. Neutropenia Biologic Drug Treatment Market Company Profiles
  • 30.2.1. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Neutropenia Biologic Drug Treatment Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. F. Hoffmann-La Roche Ltd
• 31.3. Merck & Co. Inc.
• 31.4. Johnson & Johnson
• 31.5. Baxter International Inc.
• 31.6. Mylan N.V.
• 31.7. Celgene Corporation
• 31.8. Biogen Inc.
• 31.9. AbbVie Inc.
• 31.10. Regeneron Pharmaceuticals Inc.
• 31.11. AstraZeneca plc
• 31.12. Eli Lilly and Company
• 31.13. Takeda Pharmaceutical Company Limited
• 31.14. Bayer AG
• 31.15. Sun Pharmaceutical Industries Ltd.

32. Global Neutropenia Biologic Drug Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neutropenia Biologic Drug Treatment Market

34. Recent Developments In The Neutropenia Biologic Drug Treatment Market

35. Neutropenia Biologic Drug Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Neutropenia Biologic Drug Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Neutropenia Biologic Drug Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Neutropenia Biologic Drug Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer